SNAI2 and neoplasm: In particular, the anti-inflammatory potential of ralimetinib, which, as shown here, is completed by the anti-tumor effect on pEMT tumor cells, would indicate its relevance in the context of therapy-resistant HNSCC, where the inflammatory TME confirms the pEMT by protein stabilization of Slug.